Business Context and Reporting Period
Company: Relmada Therapeutics, Inc. (RLMD)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Relmada is a clinical-stage biotechnology company focused on two primary product candidates: NDV-01 (a sustained-release formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer) and sepranolone (a neurosteroid for Prader-Willi Syndrome and Tourette Syndrome). The company terminated its esmethadone and psilocybin programs in 2025 to focus resources on these new assets.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(31,966,141) | $(27,425,907) |
| Loss Per Share (Basic & Diluted) | $(0.32) | $(0.86) |
| Operating Cash Flow | $(24,673,921) | $(24,468,909) |
| Cash & Cash Equivalents (End of Period) | $11,334,370 | $1,353,351 |
| Short-term Investments | $206,396,805 | $89,509,710 |
| Total Current Assets | $219,039,677 | $93,983,971 |
| Total Current Liabilities | $7,420,773 | $6,430,527 |
| Stockholders' Equity | $206,558,323 | $86,512,013 |
Material Changes vs. Prior Period
- Capital Raise: The company significantly strengthened its balance sheet through a private placement in March 2026, raising approximately $150 million in net proceeds. This followed a $94 million offering in November 2025.
- Liquidity Position: Total liquid assets (cash and short-term investments) increased from approximately $93 million at year-end 2025 to over $217 million as of June 30, 2026.
- Operating Expenses:
- R&D Expenses: Increased to $16.48 million (6 months) from $14.77 million, driven by a $5.2 million increase in manufacturing and drug storage costs for NDV-01 and sepranolone.
- G&A Expenses: Increased to $17.99 million from $13.67 million, primarily due to a $4.76 million increase in compensation and a $3.6 million increase in stock appreciation rights (SAR) expense.
- Investment Income: Interest and investment income rose to $3.26 million from $0.76 million due to higher average investment balances.
Guidance, Outlook, and Risks
- Clinical Milestones: Management expects to file U.S. Investigational New Drug (IND) applications for both NDV-01 and sepranolone by year-end 2026. Phase 3 trials for NDV-01 are anticipated to begin upon IND clearance.
- Liquidity Outlook: Management believes current cash and short-term investments are sufficient to fund operations for at least 12 months from the date of the report.
- Risks:
- Going Concern: The company has incurred losses since inception and expects to continue doing so until commercialization. Future funding may be required for subsequent clinical trials.
- Development Risk: No assurance exists that R&D will be successful or that products will receive regulatory approval.
- Stock-Based Compensation: Significant non-cash expenses related to Stock Appreciation Rights (SARs) and options continue to impact net loss.
Key Facts for Investor Verification
- Capital Efficiency: Verify the burn rate relative to the $217 million in liquid assets to confirm the 12-month runway estimate.
- NDV-01 Progress: Confirm the timeline for the U.S. IND filing and the specific design of the planned Phase 3 trials (high-risk BCG-unresponsive and intermediate-risk adjuvant settings).
- Sepranolone Data: Review the Phase 2a data for Tourette Syndrome and the plan for the Phase 2b study in Prader-Willi Syndrome.
- Liability Exposure: Note the $5.08 million liability for cash-settled Stock Appreciation Rights (SARs) and the potential for future cash outflows upon exercise.
- Dilution: Monitor the impact of outstanding options (~14.9 million) and warrants (~6.3 million) on future share count.